{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:00:45Z","timestamp":1794614445063,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is growing evidence that ceramides play a significant role in the onset and progression of non-alcoholic fatty liver disease (NAFLD), a highly prevalent condition in patients with type 2 diabetes associated with hepatic and cardiovascular events. However, the relationship between plasma ceramide levels and NAFLD severity in type 2 diabetes remains unclear. The main purpose of the present study was to investigate whether circulating levels of ceramides in patients with type 2 diabetes are associated with liver steatosis assessed by the highly accurate magnetic resonance imaging proton density fat fraction (MRI-PDFF). The secondary objective was to assess the relationship between plasma ceramides and noninvasive scores of liver fibrosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cross-sectional single-center study, plasma concentrations of 7 ceramides were measured by liquid chromatography-mass spectrometry in 255 patients with type 2 diabetes (GEPSAD cohort). Liver fat content was assessed by MRI-PDFF, and noninvasive scores of liver fibrosis (i.e. Fibrosis-4 index, NAFLD Fibrosis Score, FibroTest\u00ae and Fibrotic NASH Index) were calculated. A validation cohort of 80 patients with type 2 diabetes was also studied (LIRA-NAFLD cohort).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Liver steatosis, defined as a liver fat content\u2009&gt;\u20095.56%, was found in 62.4 and 82.5% of individuals with type 2 diabetes in the GEPSAD and LIRA-NAFLD cohorts, respectively. In GEPSAD, MRI-PDFF-measured liver fat content was positively associated with plasma levels of total ceramides (r\u2009=\u20090.232, p\u2009=\u20090.0002), and 18:0, 20:0, 22:0 and 24:0 ceramides in univariate analysis (p\u2009\u2264\u20090.0003 for all). In multivariate analysis, liver fat content remained significantly associated with total ceramides (p\u2009=\u20090.001), 18:0 (p\u2009=\u20090.006), 22:0 (p\u2009=\u20090.0009) and 24:0 ceramides (p\u2009=\u20090.0001) in GEPSAD, independently of age, diabetes duration, body mass index and dyslipidemia. Overall, similar relationship between plasma ceramides and liver fat content was observed in the LIRA-NAFLD validation cohort. No significant association was found between plasma ceramides and noninvasive scores of fibrosis after adjustment for age in both cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Plasma ceramide levels are associated with liver steatosis in patients with type 2 diabetes, independently of traditional risk factors for NAFLD. The independent association between plasma ceramides and liver steatosis adds new insights regarding the relationship between ceramides and NAFLD in type 2 diabetes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-02049-2","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:02:03Z","timestamp":1699462923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Plasma ceramides are associated with MRI-based liver fat content but not with noninvasive scores of liver fibrosis in patients with type 2 diabetes"],"prefix":"10.1186","volume":"22","author":[{"given":"Damien","family":"Denimal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"B\u00e9land-Bonenfant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Pais-de-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Duvillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2049_CR1","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2337\/dc20-1997","volume":"44","author":"R Lomonaco","year":"2021","unstructured":"Lomonaco R, Godinez Leiva E, Bril F, Shrestha S, Mansour L, Budd J, et al. Advanced liver fibrosis is common in patients with type 2 Diabetes followed in the outpatient setting: the need for systematic screening. Diabetes Care. 2021;44:399\u2013406.","journal-title":"Diabetes Care"},{"key":"2049_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00125-016-3902-y","volume":"59","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD)","year":"2016","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD). European Association for the Study of Obesity (EASO). EASL\u2013EASD\u2013EASO clinical practice guidelines for the management of non-alcoholic fatty Liver Disease. Diabetologia. 2016;59:1121\u201340.","journal-title":"Diabetologia"},{"key":"2049_CR3","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1053\/j.gastro.2016.02.066","volume":"150","author":"MV Machado","year":"2016","unstructured":"Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150:1769\u201377.","journal-title":"Gastroenterology"},{"key":"2049_CR4","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377:2063\u201372.","journal-title":"N Engl J Med"},{"key":"2049_CR5","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","volume":"18","author":"RH Choi","year":"2021","unstructured":"Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of Cardiovascular Disease. Nat Rev Cardiol. 2021;18:701\u201311.","journal-title":"Nat Rev Cardiol"},{"key":"2049_CR6","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.cmet.2021.06.006","volume":"33","author":"CD Green","year":"2021","unstructured":"Green CD, Maceyka M, Cowart LA, Spiegel S. Sphingolipids in metabolic Disease: the good, the bad, and the unknown. Cell Metab. 2021;33:1293\u2013306.","journal-title":"Cell Metab"},{"key":"2049_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm10040792","volume":"10","author":"E Hajduch","year":"2021","unstructured":"Hajduch E, Lachkar F, Ferr\u00e9 P, Foufelle F. Roles of ceramides in non-alcoholic fatty Liver Disease. J Clin Med. 2021;10:792.","journal-title":"J Clin Med"},{"key":"2049_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.7150\/ijbs.78525","volume":"19","author":"C Zhu","year":"2023","unstructured":"Zhu C, Huai Q, Zhang X, Dai H, Li X, Wang H. Insights into the roles and pathomechanisms of ceramide and sphigosine-1-phosphate in nonalcoholic fatty Liver Disease. Int J Biol Sci. 2023;19:311\u201330.","journal-title":"Int J Biol Sci"},{"key":"2049_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2019.00665","volume":"10","author":"M Jiang","year":"2019","unstructured":"Jiang M, Li C, Liu Q, Wang A, Lei M. Inhibiting ceramide synthesis attenuates hepatic steatosis and fibrosis in rats with non-alcoholic fatty Liver Disease. Front Endocrinol. 2019;10:1\u20138.","journal-title":"Front Endocrinol"},{"key":"2049_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1126\/science.aav3722","volume":"365","author":"B Chaurasia","year":"2019","unstructured":"Chaurasia B, Tippetts TS, Monibas RM, Liu J, Li Y, Wang L, et al. Targeting a ceramide double bond improves insulin resistance and hepatic steatosis. Science. 2019;365:386\u201392.","journal-title":"Science"},{"key":"2049_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cmet.2015.06.007","volume":"22","author":"JY Xia","year":"2015","unstructured":"Xia JY, Holland WL, Kusminski CM, Sun K, Sharma AX, Pearson MJ, et al. Targeted induction of ceramide degradation leads to improved systemic metabolism and reduced hepatic steatosis. Cell Metab. 2015;22:266\u201378.","journal-title":"Cell Metab"},{"key":"2049_CR12","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","volume":"75","author":"GJ Ooi","year":"2021","unstructured":"Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75:524\u201335.","journal-title":"J Hepatol"},{"key":"2049_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","volume":"41","author":"M Apostolopoulou","year":"2018","unstructured":"Apostolopoulou M, Gordillo R, Koliaki C, Gancheva S, Jelenik T, De Filippo E, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care. 2018;41:1235\u201343.","journal-title":"Diabetes Care"},{"key":"2049_CR14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/CIRCULATIONAHA.116.024261","volume":"135","author":"DD Wang","year":"2017","unstructured":"Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, et al. Plasma ceramides, mediterranean diet, and incident Cardiovascular Disease in the PREDIMED trial. Circulation. 2017;135:2028\u201340.","journal-title":"Circulation"},{"key":"2049_CR15","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery Disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37:1967\u201376.","journal-title":"Eur Heart J"},{"key":"2049_CR16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/clinchem\/hvac158","volume":"68","author":"TT Katajam\u00e4ki","year":"2022","unstructured":"Katajam\u00e4ki TT, Koivula M-K, Hilvo M, L\u00e4\u00e4peri MTA, Salminen MJ, Viljanen AM, et al. Ceramides and phosphatidylcholines associate with Cardiovascular Diseases in the elderly. Clin Chem. 2022;68:1502\u20138.","journal-title":"Clin Chem"},{"key":"2049_CR17","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.116.023233","volume":"134","author":"ZH Alshehry","year":"2016","unstructured":"Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 Diabetes Mellitus. Circulation. 2016;134:1637\u201350.","journal-title":"Circulation"},{"key":"2049_CR18","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.diabet.2023.101432","volume":"49","author":"S B\u00e9land-Bonenfant","year":"2023","unstructured":"B\u00e9land-Bonenfant S, Rouland A, Petit J-M, Verg\u00e8s B. Concise review of lipidomics in nonalcoholic fatty Liver Disease. Diabetes Metab. 2023;49:101432.","journal-title":"Diabetes Metab"},{"key":"2049_CR19","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.xcrm.2020.100154","volume":"1","author":"A Carlier","year":"2020","unstructured":"Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, et al. Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty Liver Disease severity in type 2 Diabetes. Cell Rep Med. 2020;1:100154.","journal-title":"Cell Rep Med"},{"key":"2049_CR20","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1007\/s00125-018-4720-1","volume":"61","author":"IJ Neeland","year":"2018","unstructured":"Neeland IJ, Singh S, McGuire DK, Vega GL, Roddy T, Reilly DF, et al. Relation of plasma ceramides to visceral adiposity, insulin resistance and the development of type 2 Diabetes Mellitus: the Dallas Heart Study. Diabetologia. 2018;61:2570\u20139.","journal-title":"Diabetologia"},{"key":"2049_CR21","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jhep.2014.11.002","volume":"62","author":"K Anjani","year":"2015","unstructured":"Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot J-L, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol. 2015;62:905\u201312.","journal-title":"J Hepatol"},{"key":"2049_CR22","doi-asserted-by":"publisher","first-page":"109829","DOI":"10.1016\/j.diabres.2022.109829","volume":"186","author":"MD Gadgil","year":"2022","unstructured":"Gadgil MD, Sarkar M, Sands C, Lewis MR, Herrington DM, Kanaya AM. Associations of NAFLD with circulating ceramides and impaired glycemia. Diabetes Res Clin Pract. 2022;186:109829.","journal-title":"Diabetes Res Clin Pract"},{"key":"2049_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jhep.2010.01.008","volume":"52","author":"SS Lee","year":"2010","unstructured":"Lee SS, Park SH, Kim HJ, Kim SY, Kim M-Y, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. J Hepatol. 2010;52:579\u201385.","journal-title":"J Hepatol"},{"key":"2049_CR24","first-page":"407","volume":"102","author":"JM Petit","year":"2017","unstructured":"Petit JM, Cercueil JP, Loffroy R, Denimal D, Bouillet B, Fourmont C, et al. Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 Diabetes: the Lira-NAFLD study. J Clin Endocrinol Metab. 2017;102:407\u201315.","journal-title":"J Clin Endocrinol Metab"},{"key":"2049_CR25","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S144\u201374.","DOI":"10.2337\/dc22-S010"},{"key":"2049_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1148\/radiol.2493080217","volume":"250","author":"B Guiu","year":"2009","unstructured":"Guiu B, Petit J-M, Loffroy R, Ben Salem D, Aho S, Masson D, et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology. 2009;250:95\u2013102.","journal-title":"Radiology"},{"key":"2049_CR27","doi-asserted-by":"publisher","first-page":"E462","DOI":"10.1152\/ajpendo.00064.2004","volume":"288","author":"LS Szczepaniak","year":"2005","unstructured":"Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab. 2005;288:E462\u2013468.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2049_CR28","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.cgh.2022.03.044","volume":"21","author":"F Tavaglione","year":"2023","unstructured":"Tavaglione F, Jamialahmadi O, De Vincentis A, Qadri S, Mowlaei ME, Mancina RM, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2023;21:1523\u20131532e1.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR29","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/hep.21496","volume":"45","author":"P Angulo","year":"2007","unstructured":"Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846\u201354.","journal-title":"Hepatology"},{"key":"2049_CR30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"2049_CR31","doi-asserted-by":"publisher","first-page":"16328","DOI":"10.1074\/jbc.M115.709626","volume":"291","author":"TTT Tran","year":"2016","unstructured":"Tran TTT, Postal BG, Demignot S, Ribeiro A, Osinski C, Pais de Barros J-P, et al. Short-term palmitate supply impairs intestinal insulin signaling via ceramide production. J Biol Chem. 2016;291:16328\u201338.","journal-title":"J Biol Chem"},{"key":"2049_CR32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461\u201370.","journal-title":"Ann Intern Med"},{"key":"2049_CR33","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1111\/apt.12963","volume":"40","author":"L Fedchuk","year":"2014","unstructured":"Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty Liver Disease. Aliment Pharmacol Ther. 2014;40:1209\u201322.","journal-title":"Aliment Pharmacol Ther"},{"key":"2049_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.jhep.2021.05.025","volume":"75","author":"European Association for the Study of the Liver","year":"2021","unstructured":"European Association for the Study of the Liver. Clinical Practice Guideline Panel, Chair:, EASL Governing Board representative:, panel members: EASL Clinical Practice guidelines on non-invasive tests for evaluation of Liver Disease severity and prognosis \u2013 2021 update. J Hepatol. 2021;75:659\u201389.","journal-title":"J Hepatol"},{"key":"2049_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2337\/dc23-S004","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes-2023. Diabetes Care. 2023;46:49\u201367.","journal-title":"Diabetes Care"},{"key":"2049_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1097\/MOL.0000000000000806","volume":"33","author":"RN Lemaitre","year":"2022","unstructured":"Lemaitre RN, King IB. Very long-chain saturated fatty acids and Diabetes and Cardiovascular Disease. Curr Opin Lipidol. 2022;33:76\u201382.","journal-title":"Curr Opin Lipidol"},{"key":"2049_CR37","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cgh.2022.02.059","volume":"21","author":"J Boursier","year":"2023","unstructured":"Boursier J, Canivet CM, Costentin C, Lannes A, Delamarre A, Sturm N, et al. Impact of type 2 Diabetes on the accuracy of noninvasive tests of liver fibrosis with resulting clinical implications. Clin Gastroenterol Hepatol. 2023;21:1243\u20131251e12.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2049_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/db08-1228","volume":"58","author":"JM Haus","year":"2009","unstructured":"Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, et al. Plasma ceramides are elevated in obese subjects with type 2 Diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58:337\u201343.","journal-title":"Diabetes"},{"key":"2049_CR39","doi-asserted-by":"publisher","first-page":"677202","DOI":"10.3389\/fendo.2022.677202","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hu Y, An Y, Wang Q, Liu J, Wang G. The changes of lipidomic profiles reveal therapeutic effects of exenatide in patients with type 2 Diabetes. Front Endocrinol. 2022;13:677202.","journal-title":"Front Endocrinol"},{"key":"2049_CR40","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-023-01845-0","volume":"22","author":"D Denimal","year":"2023","unstructured":"Denimal D, Bergas V, Pais-de-Barros J-P, Simoneau I, Demizieux L, Passilly-Degrace P, et al. Liraglutide reduces plasma dihydroceramide levels in patients with type 2 Diabetes. Cardiovasc Diabetol. 2023;22:104.","journal-title":"Cardiovasc Diabetol"},{"key":"2049_CR41","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.bbalip.2014.09.009","volume":"1841","author":"W-J Park","year":"2014","unstructured":"Park W-J, Park J-W, Merrill AH, Storch J, Pewzner-Jung Y, Futerman AH. Hepatic fatty acid uptake is regulated by the sphingolipid acyl chain length. Biochim Biophys Acta. 2014;1841:1754\u201366.","journal-title":"Biochim Biophys Acta"},{"key":"2049_CR42","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3892\/mmr.2015.3361","volume":"12","author":"J-F Li","year":"2015","unstructured":"Li J-F, Qu F, Zheng S-J, Ren F, Wu H-L, Liu M, et al. Plasma sphingolipids: potential biomarkers for severe hepatic fibrosis in chronic Hepatitis C. Mol Med Rep. 2015;12:323\u201330.","journal-title":"Mol Med Rep"},{"key":"2049_CR43","doi-asserted-by":"publisher","first-page":"e0138130","DOI":"10.1371\/journal.pone.0138130","volume":"10","author":"G Grammatikos","year":"2015","unstructured":"Grammatikos G, Ferreir\u00f2s N, Waidmann O, Bon D, Schroeter S, Koch A, et al. Serum sphingolipid variations associate with hepatic decompensation and survival in patients with Cirrhosis. PLoS ONE. 2015;10:e0138130.","journal-title":"PLoS ONE"},{"key":"2049_CR44","doi-asserted-by":"publisher","first-page":"E45","DOI":"10.1210\/jc.2013-2559","volume":"99","author":"K Tarasov","year":"2014","unstructured":"Tarasov K, Ekroos K, Suoniemi M, Kauhanen D, Sylv\u00e4nne T, Hurme R, et al. Molecular lipids identify cardiovascular risk and are efficiently lowered by simvastatin and PCSK9 deficiency. J Clin Endocrinol Metab. 2014;99:E45\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"2049_CR45","doi-asserted-by":"publisher","first-page":"E2335","DOI":"10.1210\/jc.2014-1665","volume":"99","author":"TWK Ng","year":"2014","unstructured":"Ng TWK, Ooi EMM, Watts GF, Chan DC, Weir JM, Meikle PJ, et al. Dose-dependent effects of rosuvastatin on the plasma sphingolipidome and phospholipidome in the metabolic syndrome. J Clin Endocrinol Metab. 2014;99:E2335\u201340.","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-02049-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-02049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T17:04:29Z","timestamp":1699463069000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-02049-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2049"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-02049-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,8]]},"assertion":[{"value":"28 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the Declaration of Helsinki and was approved by our regional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"310"}}